End-of-life medications are a small set of drugs kept on hand, and sometimes administered continuously, to control the symptoms that commonly arise as a person’s body shuts down. They target pain, breathlessness, nausea, agitation, and noisy airway secretions. The goal is comfort, not cure, and the pharmacology behind each drug class is straightforward once you know what symptom it addresses. What often surprises families is how few medications are actually involved and how much of the work revolves around timing, route of delivery, and honest conversations about what the drugs can and cannot do.
The Core Set of Medications
In the United Kingdom, prescribing four injectable medications for end-of-life symptoms is standard practice, guided by both local and national policies. These four cover pain, nausea and vomiting, agitation, and noisy respiratory secretions.1PubMed Central. Anticipatory prescribing in community end-of-life care: systematic review and narrative synthesis of the evidence since 2017 Other countries use similar frameworks, though which specific drugs fill each role can vary. The idea is the same everywhere: have a compact toolkit ready so that when a symptom flares, the response is measured in minutes rather than hours of scrambling for a prescription.
These medications are often prescribed “anticipatorily,” meaning a doctor writes the prescription while the patient is still relatively stable, and the drugs sit in the home or hospice facility until needed. GPs describe it as an insurance plan. One qualitative study of UK general practitioners found that doctors preferred to prescribe early because predicting the timing and exact symptoms of dying is genuinely difficult, especially in conditions like advanced dementia or multi-organ frailty.2British Journal of General Practice. GPs’ decisions about prescribing end-of-life anticipatory medications: a qualitative study In some cases, the medications sit unused for months or even expire. Clinicians generally see that as acceptable because the alternative, a crisis at 2 a.m. with no drugs available, is far worse.
Healthcare professionals broadly report that anticipatory prescribing provides reassurance and may help prevent panicked hospital admissions. What is less established is how patients themselves feel about having these drugs in their home. A systematic review noted that the attitudes of patients toward anticipatory prescribing remain essentially unknown, and the evidence that it improves actual symptom control is thin.3PubMed Central. Anticipatory prescribing of injectable medications for adults at the end of life in the community: A systematic literature review and narrative synthesis The practice persists largely on clinical consensus and pragmatic logic rather than on trial data showing better outcomes.
Opioids for Pain and Breathlessness
Morphine is the workhorse. A systematic review of opioid use for end-of-life breathlessness found that morphine was the most studied drug, appearing in thirteen of twenty-three included studies. Fentanyl, oxycodone, and hydromorphone also appeared, delivered by injection, mouth, or sometimes nebulizer.4PubMed. Opioid Management of Dyspnea at End of Life: A Systematic Review Sedation was the most frequently reported side effect, which at this stage of care is often considered an acceptable trade-off rather than a problem.
Opioids work by binding to receptors in the brain and spinal cord that dampen the perception of pain and reduce the brain’s alarm response to low oxygen levels. That second property is why they help with the sensation of air hunger, even when there is nothing structurally wrong with the lungs. The dose used for comfort at the end of life is typically titrated upward gradually, with the care team watching for adequate relief. A common fear among families is that opioids will hasten death. Research on palliative sedation, which often involves opioids alongside other agents, has found no detrimental effect on survival when medications are used at doses appropriate to the symptom burden.5PubMed. Palliative sedation in end-of-life care and survival: a systematic review The distinction matters: the intent is to relieve suffering, and the doses required to do that do not appear to shorten life.
Nausea and Vomiting
Nausea near the end of life can stem from many sources: the disease itself, medications, bowel problems, or metabolic changes as organs fail. The traditional palliative care approach tries to figure out where in the body the nausea signal originates and then match a drug to the right receptor. In practice, that sounds more precise than it is. A review of the evidence found the scientific basis for this receptor-matching strategy to be limited, partly because the neuropharmacology underlying nausea is not as tidy in dying patients as textbooks suggest.6PubMed Central. Treating nausea and vomiting in palliative care: a review
The drugs most often reached for include haloperidol (a dopamine blocker commonly associated with psychiatric use but effective against nausea), metoclopramide (which helps the stomach empty), and cyclizine (an antihistamine). Haloperidol in particular is valued in palliative care for pulling double duty: it treats both nausea and the delirium that can accompany the final days.7PubMed. Haloperidol in palliative care Dexamethasone, a corticosteroid, sometimes gets added when nausea is driven by swelling around a tumor or raised pressure inside the skull.
Agitation, Restlessness, and Delirium
Terminal restlessness is one of the most distressing things families witness. A person who was calm and drowsy may suddenly become agitated, pulling at sheets, calling out, or appearing frightened. The causes overlap: delirium from organ failure, uncontrolled pain, a full bladder, medication side effects, or simply the neurological changes of dying.
Midazolam, a fast-acting benzodiazepine, is considered one of the four essential drugs for quality end-of-life care. It works by boosting the activity of a brain chemical called GABA, which has calming, anti-anxiety, and anticonvulsant properties.8PubMed Central. Midazolam: an essential palliative care drug Its onset is quick, especially when given by injection under the skin, and its duration is short enough that care teams can adjust the dose without committing the patient to hours of deep sedation.
Haloperidol remains the most widely recommended drug for delirium specifically, appearing in consensus-based guidelines around the world. The evidence supporting it is not strong by clinical-trial standards, though. A review of pharmacological treatment for terminal agitation noted that high-quality evidence for haloperidol’s efficacy is missing and that adding a benzodiazepine may improve control of agitation or refractory delirium.9PubMed Central. Pharmacological Treatment for Terminal Agitation, Delirium and Anxiety in Frail Older Patients In practice, clinicians often combine the two: haloperidol for the delirium itself and midazolam as a backup when agitation does not settle.
Airway Secretions and the “Death Rattle”
As a person loses the ability to cough or swallow, saliva and mucus pool in the throat and airway, producing a gurgling sound with each breath. This is colloquially called the death rattle. It is almost certainly more distressing to the people at the bedside than to the dying person, who is usually deeply unconscious by this point.
Anticholinergic drugs like hyoscine butylbromide (also known as scopolamine butylbromide), glycopyrronium, and atropine are used to dry up these secretions. The strongest evidence favors giving hyoscine butylbromide preventively before the rattle starts. One study found that prophylactic use cut the rate of developing death rattle roughly in half compared to placebo.10PubMed Central. Reducing death rattle at the end of life Once the rattle has already established itself, the evidence is less encouraging. A randomized trial of sublingual atropine versus placebo found no significant difference in noise reduction at either two or four hours.11PubMed. Randomized double-blind trial of sublingual atropine vs. placebo for the management of death rattle
There is no evidence that treating the death rattle improves the dying person’s comfort. The real beneficiaries are the family members and caregivers in the room. That is a legitimate reason to use the medication, but clinicians are encouraged to have that honest conversation: this is for you, the family, not for your loved one.10PubMed Central. Reducing death rattle at the end of life
How the Medications Are Delivered
When a person can no longer swallow pills, the route of delivery shifts. The most common alternative in palliative care is the subcutaneous route, meaning a small needle placed just under the skin, often in the upper arm, thigh, or abdomen. Medications can be given as individual injections or as a continuous infusion through a portable pump called a syringe driver. Syringe drivers have been a mainstay of British palliative care since the early 1980s and allow multiple compatible drugs to be mixed in a single syringe and delivered steadily over 24 hours.12PubMed. The syringe driver and the subcutaneous route in palliative care: the inventor, the history and the implications
Other routes include buccal (placed between the cheek and gum), sublingual (under the tongue), rectal, and transdermal patches. Fentanyl patches, for instance, deliver a steady dose of opioid through the skin over several days without requiring any swallowing or injection. The choice depends on the symptom, the available drug formulations, and the care setting. In hospice at home, simplicity matters: a syringe driver that a district nurse checks once a day is far more practical than repeated injections requiring a professional visit each time.
For seizure management in dying patients, buccal or intranasal midazolam and subcutaneous options offer alternatives when oral medications are no longer feasible. Timely treatment of seizures is important not just for comfort but because uncontrolled seizures can trigger unnecessary emergency hospital admissions.13PubMed. Management of prolonged epileptic seizures and status epilepticus in palliative care patients
Corticosteroids and the “Boost”
Dexamethasone is one of the most commonly prescribed adjuvant drugs in end-of-life care for people with advanced cancer. It does not treat any single symptom neatly; instead, it can temporarily reduce swelling, improve appetite, ease breathlessness, and lift energy levels in a way that patients and families describe as a “boost.”14PubMed. A retrospective observation of corticosteroid use at the end of life in a hospice In advanced cancer patients, it is frequently prescribed alongside other medications for symptoms like pain, fatigue, and poor appetite.15PubMed. Do Patients Benefit from a Trial of Corticosteroids at the End of Life?
This versatility has a downside. Because dexamethasone can make people feel temporarily better, increase their appetite, and alter the body’s stress response, it can mask the signs that death is approaching. A case report documented how dexamethasone use made it difficult to recognize the dying phase, concealing hallmarks like being bedbound, drinking only sips, and becoming semiconscious.16PubMed. Can the Dying Phase Be Masked by the Use of Dexamethasone? A Case Report Families may interpret the temporary rally as improvement, only to be blindsided when the person deteriorates. Clinicians need to be upfront that corticosteroids buy comfort, sometimes remarkably so, but they do not change the trajectory.
Palliative Sedation
When standard medications at standard doses cannot control a symptom, clinicians may turn to palliative sedation: deliberately reducing a person’s level of consciousness to relieve suffering that has become truly intractable. This is not the same as simply giving an extra dose of midazolam. Palliative sedation is a defined clinical intervention with its own ethical framework and classification. It can be intermittent or continuous, light or deep, and targeted to physical symptoms like refractory pain or to psychological distress like intractable existential anguish.17PubMed Central. The role of end-of-life palliative sedation: medical and ethical aspects – Review
A systematic review examining whether palliative sedation shortens life in cancer patients concluded that it does not appear to have any detrimental effect on survival when appropriately indicated and correctly dosed.5PubMed. Palliative sedation in end-of-life care and survival: a systematic review This finding is critical for families grappling with the decision. Agreeing to palliative sedation is not agreeing to hasten death. It is agreeing that consciousness is no longer serving the patient’s well-being and that the humane choice is to let them rest.
Deprescribing at the End of Life
An often overlooked part of end-of-life medication management is stopping drugs rather than starting them. People who are dying may still be taking a statin for cholesterol, a blood pressure pill, or a diabetes medication. These drugs were prescribed for long-term prevention, and when the time horizon has shortened to days or weeks, the benefits vanish while the burden remains. Swallowing multiple tablets when you can barely drink is miserable, and each unnecessary drug carries a risk of side effects or interactions. Deprescribing is the process of reviewing and withdrawing medications that no longer serve the patient, and there is evidence that stopping preventive medications in this context is safe.18PubMed Central. Deprescribing in palliative care
Families sometimes resist deprescribing because stopping a medication feels like giving up. Clinicians find it helpful to reframe the conversation: the goal of care has shifted from preventing future disease to maximizing comfort right now, and the best way to do that is to remove anything that does not directly contribute to how the person feels today.
What Families Actually Struggle With
Even when the right medications are prescribed and sitting in the bedside drawer, someone has to give them. In home hospice settings, that someone is usually a family caregiver with no medical training. About a third of hospice providers in one US survey reported frequently encountering caregivers who had trouble managing medications.19PubMed Central. Hospice experiences and approaches to support and assess family caregivers in managing medications for home hospice patients: A providers survey Roughly the same proportion of professionals said they found it difficult to teach and support caregivers in this task.
A qualitative study of family caregivers in China documented the specific pressure points. Caregivers struggled to tell whether their loved one was in pain, to figure out the right dose, to access the medications they needed, and to manage the emotional weight of potentially making a mistake.20PubMed Central. Family caregivers’ administration of medications at the end-of-life in China: a qualitative study Financial barriers, regulatory restrictions on controlled substances, and geographic inequality in pharmacy access compounded the problem. These challenges are not unique to China; opioid regulations, rural pharmacy closures, and caregiver anxiety are global issues.
If you are the person who will be giving medications at home, ask the hospice team for hands-on demonstration, not just written instructions. Practicing with an oral syringe or a subcutaneous injection on a foam pad while a nurse watches is far more useful than reading a leaflet at 3 a.m. when your loved one is in distress.
Managing Less Common Symptoms
Not every dying person follows the textbook trajectory of pain, nausea, agitation, and secretions. Some face specific complications that require additional medications.
Malignant bowel obstruction, where a tumor blocks the intestine, causes severe nausea, vomiting, and abdominal pain. When surgery is not an option, medical management becomes the focus. A combination approach using dexamethasone, octreotide (a drug that reduces gut secretions), and metoclopramide has shown some promise. One phase 2 study found that all patients who completed treatment had complete resolution of nausea, along with improvements in pain, constipation, and ability to eat.21PubMed. Palliative Management of Inoperable Malignant Bowel Obstruction: Prospective, Open Label, Phase 2 Study at an NCI Comprehensive Cancer Center A separate randomized trial of octreotide alone was less impressive, finding no significant reduction in vomiting-free days compared to placebo, though a secondary analysis suggested fewer individual vomiting episodes in the octreotide group.22PubMed. Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction The combination approach may matter more than any single agent.
Seizures are another concern, particularly for people with brain tumors or a history of epilepsy. In the palliative setting, the priority is rapid control through routes that do not require swallowing. Buccal midazolam is the most accessible option for caregivers to administer at home, and subcutaneous infusions can be set up for patients at high risk of recurrent seizures.13PubMed. Management of prolonged epileptic seizures and status epilepticus in palliative care patients
How Palliative Medications Differ From Aid-in-Dying Drugs
Families sometimes conflate end-of-life comfort medications with medical aid in dying (sometimes called assisted suicide or euthanasia, depending on the jurisdiction). The pharmacology is completely different. Palliative medications aim to control symptoms while the disease runs its course. Aid-in-dying protocols use drugs at doses specifically intended to end life.
A scoping review covering practices between 1989 and 2020 across several countries found that the most common lethal agents in assisted suicide are high-dose barbiturates, usually pentobarbital or secobarbital. In US states where aid in dying is legal, multi-drug combinations have been used that include diazepam, digoxin, morphine, and either amitriptyline or propranolol. In countries where euthanasia is practiced by clinicians, the drug protocols vary further and may include neuromuscular blocking agents and cardiotoxic drugs.23PubMed Central. Efficacy and safety of drugs used for ‘assisted dying’ These are fundamentally different substances at fundamentally different doses compared to the morphine and midazolam a hospice nurse administers for comfort. The overlap in drug names (morphine appears in both lists, for instance) can cause confusion, but the intent, the dose, and the expected outcome are not the same thing.
Understanding this distinction is important not just ethically but practically. Families who fear that accepting a morphine drip for comfort means they are choosing euthanasia may refuse effective symptom control and condemn their loved one to unnecessary suffering. The evidence is clear that appropriately dosed palliative medications do not shorten life. They make the time remaining bearable.